Improving the therapeutic efficacy of neural progenitor cell transplantation following spinal cord injury.
Improving the therapeutic efficacy of neural progenitor cell transplantation following spinal cord injury.
复制标题
DOI：
10.1080/14737175.2017.1270206
复制
发表时间：
2017-05
影响因子：
4.3
通讯作者：
Fischer I
中科院分区：
文献类型：
--
作者：
Lane MA;Lepore AC;Fischer I
已经有广泛的临床前研究测试细胞疗法来修复受损的脊髓，但由于疗效不一致，急性/亚急性SCI患者数量有限以及临床试验成本高，这些研究仍然是一个挑战。本文重点介绍了神经前体细胞（NPC）的治疗潜力，因为它们可以提供能够促进脊髓损伤（SCI）后修复和增强功能改善的细胞成分。作者讨论了NPC移植的挑战，涉及神经胶质和神经元谱系的NPC的不同群体，相对于急性和慢性损伤的治疗时机，以及正在进行的临床试验的进展。临床前研究将继续阐明与NPC移植相关的恢复机制，包括增加与脊髓萎缩和多发性硬化等相关领域的合作。临床试验领域将不断扩大，包括急性和慢性SCI，生物技术、政府和学术界之间的合作伙伴关系将得到加强。还将越来越多地努力开发更好的生物标志物，成像和结果措施，以详细评估神经功能和生活质量的措施。
There have been a wide range of preclinical studies testing cellular therapies to repair the injured spinal cord, yet they remain a challenge to translate because of inconsistencies in efficacy, limited number of patients with acute/subacute SCI and the high costs of clinical trials. This paper focusses on the therapeutic potential of neural precursor cells (NPCs) because they can provide the cellular components capable of promoting repair and enhancing functional improvement following spinal cord injury (SCI). The authors discuss the challenges of NPC transplantation with respect to different populations of NPCs of glial and neuronal lineages, the timing of treatment relative to acute and chronic injury, and the progress in ongoing clinical trials. Preclinical research will continue to elucidate mechanisms of recovery associated with NPC transplants, including increasing the partnership with related fields such as spinal atrophies and multiple sclerosis. The clinical trials landscape will grow and include both acute and chronic SCI with increased partnership and strengthened communication between biotechnology, government and academia. There will also be growing effort to develop better biomarkers, imaging and outcome measures for detailed assessment of neurological function and measures of quality of life.